A trial looking at celecoxib with standard treatment for certain types of cancer that have spread (LION Trial)

Cancer type:

Breast cancer
Kidney cancer
Lung cancer
Non small cell lung cancer
Renal cell cancer
Secondary cancers

Status:

Open

Phase:

Phase 2

This trial is looking at adding a drug called celecoxib to standard treatment Open a glossary item to improve treatment for advanced cancer Open a glossary item. This is cancer that has spread into surrounding tissues or to another part of the body. 

It is for people who are having their first treatment for advanced:

  • triple negative breast cancer
  • non small cell lung cancer
  • renal cell cancer

More about this trial

You might have immunotherapy Open a glossary item as the first treatment for the following types of cancer that have spread:

Immunotherapy helps the immune system Open a glossary item to find and kill cancer cells. In some people, it doesn’t work as well as doctors had hoped. So researchers are looking at ways to improve treatment. In this trial they are looking at a drug called celecoxib. It is a non steroidal anti inflammatory drug Open a glossary item.

Inflammation can make cancers grow. This is because it can cause an enzyme called COX-2 to increase. We know from research that cancer cells with high levels of COX-2 grow more and are better at avoiding the body’s immune system. We also know from early research that anti inflammatory drugs might help immunotherapy to work better.

Celecoxib works by blocking COX-2. Celecoxib is already used to treat inflammatory conditions, like arthritis. It isn’t used currently in the treatment of cancer.

In this trial, everyone has celecoxib. You also have the standard treatment for your cancer type:

The main aims of the trial are to find out:

  • how well adding celecoxib to standard treatment works
  • more about the side effects 

Who can enter

The following bullet points are a summary of the entry conditions for this trial. Talk to your doctor or the trial team if you are unsure about any of these. They will be able to advise you. 

Who can take part

You may be able to join this trial if all of the following main entry conditions apply. You:

  • have cancer that has spread into surrounding tissues or to other parts of the body 
  • have at least one area of cancer that hasn’t been treated with radiotherapy that your doctor can measure on a scan 
  • have satisfactory blood test results 
  • have a sample of tissue that was taken within 3 months of joining the trial 
  • are suitable to have a type of immunotherapy called an immune checkpoint inhibitor 
  • are fit and active but might not be able to do heavy physical work (performance status 0 or 1)
  • are willing to use reliable contraception during the trial and for a period after if there is any chance you or your partner could become pregnant 
  • are at least 18 years old 

Triple negative breast cancer group
As well as the main entry conditions above, the following must also apply for this group. You:

  • have triple negative breast cancer confirmed with a recent tissue sample
  • have the protein PD-L1 on the breast cancer cells 
  • can’t have surgery to remove the cancer 

Non small cell lung cancer group
As well as the main entry conditions above, the following must also apply for this group. You:

  • have NSCLC recently confirmed with a tissue or fluid sample  
  • have the protein PD-L1 in more than half of the lung cancer cells. Your doctor will know this. 
  • have no evidence of the EGFR gene change (mutation Open a glossary item), the ALK gene change or the ROS1 gene change in your cancer cells. Your doctor will check this. 
  • may have previously had chemotherapy for cancer that hadn’t spread. The last dose you had must have been more than 6 months before your cancer got worse. 

Renal cell cancer group
As well as the main entry conditions above, the following must also apply for this group. You:

Who can’t take part

Cancer related 
You cannot join this trial if any of these apply. You:

  • have already had treatment for incurable cancer that has spread to surrounding tissues or to other parts of the body
  • are having chemotherapy, an experimental treatment or a targeted cancer drug Open a glossary item. You can take part if you are having bisphosphonates or denosumab for cancer spread to the bone.
  • have cancer that has spread to the brain or spinal cord and is causing symptoms or your doctor suspects you have this. You can take part if you have had treatment, the cancer is stable and you have stopped taking steroids. Open a glossary item
  • have cancer that has spread to the tissues that cover the brain and spinal cord 
  • have had another cancer in the last 5 years. You can take part if you have successfully treated non melanoma skin cancer Open a glossary item, in situ cancer Open a glossary item of the cervix, ductal carcinoma of the breast Open a glossary item or early stage cancer of the womb.

Medical conditions
You cannot join this trial if any of these apply. You:

  • have had a heart attack or heart surgery in the last 6 months or a significant heart problem Open a glossary item that needs treatment 
  • are taking certain medications that you can’t have in the trial. Your doctor will know this. 
  • break down some medicines in the body very slowly. Your doctor will test for this. 
  • have an autoimmune condition Open a glossary item that needs treatment apart from certain ones. Your doctor will know about this. 
  • have had treatment that damps down the immune system Open a glossary item. This includes steroids within 2 weeks of starting trial treatments unless it was a low dose.
  • have scarring on the lungs that is causing symptoms or could interfere with monitoring side effects that affect the lung.
  • have side effects from past treatment that aren’t getting better. You can take part if you have hair loss or white patches on your skin. 
  • have HIV, an active hepatitis B or hepatitis C infection or another infection that needs treatment to the whole body
  • regularly take aspirin, you took it regularly in the past or you take a type of drug called a non steroidal anti inflammatory drug 
  • have another medical condition or mental health condition that could affect you taking part in the trial or there is another reason the trial team think you won’t be suitable to take part 

Other
You cannot join this trial if any of these apply. You:

  • are allergic to celecoxib 
  • are allergic to a type of drug called a sulphonamide
  • have had a live vaccination Open a glossary item within 30 days of joining the trial. This is apart from the seasonal flu vaccine or the approved COVID-19 vaccines as these aren’t live.
  • are pregnant or breastfeeding 

Trial design

This is a phase 2 trial. There are 3 groups and the group you join depends on your cancer type. 

The team need:

Everyone in the trial has treatment for as long as it is working and the side effects aren’t too bad. Your doctor will talk to you about other treatment options if you stop trial treatment. 

Triple negative breast cancer
You have atezolizumab and nab-paclitaxel as a drip into a vein.

You have treatment in 4 week periods called treatment cycles Open a glossary item. In each cycle you have:

  • atezolizumab every 2 weeks
  • nab-paclitaxel once a week for 3 weeks and then have a week off

Celecoxib is a capsule. You take it twice a day every day. 

Renal cell cancer 
You have ipilimumab and nivolumab as a drip into a vein. You have it every 3 weeks. After four treatments of ipilimumab and nivolumab, you then continue to have only nivolumab. You have this every 4 weeks. 

Celecoxib is a capsule. You take it twice a day every day. 

Non small cell lung cancer
You have pembrolizumab as a drip into a vein. You have it every 3 weeks. This is ongoing. 

Celecoxib is a capsule. You take it twice a day every day. 

Patient diary
Everyone fills in a diary card. This is to record when you take celecoxib and if you miss any doses.

Samples for research 
The researchers might ask to take extra tissue samples (biopsies Open a glossary item) if there isn’t a previous sample that they can use. They also ask to have a piece of cancer tissue if you have a sample taken as part of your routine care. You don’t have to agree to give the extra tissue samples if you don’t want to. It won’t affect you taking part in the rest of the trial. 

The team ask to take some extra blood samples. Where possible, you have these at the same time as your routine blood tests.

They plan to use the samples to:

  • see how well the treatment is working
  • look for small pieces of cancer DNA in the blood (ctDNA Open a glossary item
  • look at immune cells 

You also give some urine samples if you have renal cell cancer.

The team will also ask your permission to store some samples for future research. You don’t have to agree to this.

Hospital visits

You see the doctor for a physical examination Open a glossary item and have tests before you can take part. These include:

  • blood tests
  • a urine test
  • a CT scan

You might also need to have an MRI scan

You have your standard treatment at the hospital in the outpatient department. During treatment you see the doctor regularly. This is for blood tests and to see how you are.

Trial scans
During treatment you have a CT scan once every 9 weeks. You stop having the trial scans if your cancer gets worse. 

Follow up
When you stop treatment you see the trial team one month later. The team then follow you up every 3 months. They may call you to see how you are getting on, or check your medical notes. 

Side effects

The trial team monitor you during treatment and afterwards. Contact your advice line or tell your doctor or nurse if any side effects are bad or not getting better. 

The common side effects of celecoxib include:

  • high blood pressure
  • heart problems such as heart attacks
  • stomach problems including tummy (abdominal) pain
  • indigestion
  • problems swallowing
  • diarrhoea
  • being sick 
  • an allergic reaction or skin rash
  • sinus infection Open a glossary item blocked or runny nose and flu-like symptoms 
  • infections including urine infections 
  • weight gain 
  • swollen ankles, feet or hands
  • kidney stones
  • an enlarged prostate Open a glossary item
  • dizziness
  • difficulty sleeping 
  • joint pain

Atezolizumab, pembrolizumab, nivolumab and ipilimumab can affect the immune system Open a glossary item. This may cause inflammation Open a glossary item and other reactions in different parts of the body. For many people the inflammation and reactions are not too bad. For some people they can cause serious side effects. 

These side effects could happen during treatment or months after treatment has finished. Rarely, these side effects could be life threatening. Your doctor or nurse can explain what these side effects are, the risk of them happening and what to look out for.
 
If you have any of these side effects tell your doctor or nurse as soon as possible. You should tell them that you are on or have been on an immunotherapy.

We have more information about the following drugs and their side effects: 

Location

Bath
Manchester
Rhyl
Sheffield
Truro
Wrexham

Recruitment start:

Recruitment end:

How to join a clinical trial

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Chief Investigator

Dr Anne Armstrong

Supported by

The Christie NHS Foundation Trust
The Jon Moulton Charity Trust
The Christie Charity
Liverpool Clinical Trials Centre

If you have questions about the trial please contact our cancer information nurses

Freephone 0808 800 4040

Last review date

CRUK internal database number:

19932

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Last reviewed:

Rate this page:

No votes yet
Thank you!
We've recently made some changes to the site, tell us what you think